Phase 2 N=126 Levetiracetam to Prevent Post-Traumatic Epilepsy
Epilepsy · Post-traumatic Epilepsy
Primary: Post-Traumatic Epilepsy — 6; 8 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Study of XELOX With Cetuximab in Advanced Gastric Cancer
Gastric Cancer
Primary: Overall Response Rate — 23 participants
Phase 2 N=176 Safety and Efficacy Study of Dysport RU and Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects as Responders in the ILA (Using Validated 4-point Photographic Scale) and the SSA of Glabellar Lines at Maximum Frown — 0; 88.9; 91.4; 87.9…
Phase 2 N=60 Copper Histidine Therapy for Menkes Diseases
Kinky Hair Syndrome
Primary: Gross Motor Development at 36 Mos of Age or at Death (Mos) — 13.743; 2.455; 15.667 Other - months
Phase 2 N=7 Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
Gaucher Disease, Type 3
Primary: Change From Baseline to 12 Months (Week 53) in Hemoglobin Concentration — 2.15 g/dL
Phase 2 N=40 Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Recurrent Glioblastoma Multiforme · Malignant Glioma · Adult Brain Tumor
Primary: Six-month Progression-free Survival (PFS6) — 30 percentage of participants
Phase 2 N=685 A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Plasma A1C Levels at Week 12 — -0.14; -0.36; -0.35; -0.53 Percent — p=<0.001
Phase 2 N=66 Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure
Heart Failure
Primary: Evaluate the Reduction in Left-ventricular End Systolic Volume Index (LVESVi) After 6 Months of Spinal Cord Stimulation (SCS) Therapy in the Treatment Arm Compared to…
Phase 2 N=244 Multicenter, Open-label, Safety and Tolerability Study
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs) During First 6 Weeks. — 79; 19; 7; 78 Participants
Phase 2 N=50 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Disease Progression or Death at 12 Months After Baseline — 42 percentage of participants
Phase 2 N=11 A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
Chronic Myelomonocytic Leukemia
Primary: Percentage of Patients With Complete Hematologic Response (According to IWG 2006 Criteria) in CMML Patients Treated With 5-azacitidine. — 27 percentage of patients
Phase 2 N=20 Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: Rate of Rise of Serum PSA — 0.0825 Nanograms Per Milliliter
Phase 2 N=90 Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Head and Neck Cancer · Precancerous Condition
Primary: 24-month Progression-free Survival — 64 percentage of participants
Phase 2 N=169 Bosutinib For Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney, Autosomal Dominant
Primary: Change From Baseline (CFB) in Total Kidney Volume (TKV) at Month 25 — 1686.38; 1418.96; 1487.48; 1670.33 centimeter cube (cm^3) — p=<0.0001
Phase 2 N=10 Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
Extragonadal Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Confirmed Objective Response Rate (Complete and Partial Response) as Measured by RECIST Criteria After 2 Courses of Treatment — 3; 7 participants